Sarepta Therapeutics (SRPT) Misses Q1 EPS by 15c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.15), $0.15 worse than the analyst estimate of ($1.00).

Sarepta said its pre-NDA meeting with the FDA remains calendared for second quarter 2015.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs
• Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral